$\lambda$

Rate of mAb-tumor cell complex formation

$8.9\times {10}^{-14}$

for cetuximab

$8.6\times {10}^{-14}$

for panitumumab

mg cell⁻¹ L⁻¹ day⁻¹

[32]

$h_2$

Concentration of cetuximab or panitumumab for half-maximal EGFR binding

$4.45\times {10}^{-5}$

for cetuximab

$4.3\times {10}^{-5}$

for panitumumab

mg L⁻¹

[32]

$T_K$

Carrying capacity of wild-type and mutant tumor cells combined in the absence of tumor angiogenesis

$1\times {10}^6$

cells

[50]

$g_2$

Conversion factor from number of activated endothelial cells to the increase in tumor carrying capacity

1

$\frac{\text{tumorcells}}{\text{endothelialcell}}$

Est.

$p_1$

Maximum rate of production of TGF-β by hypoxic tumor cells

$1\times {10}^5$

IU L⁻¹ day⁻¹

Est. from [50]

$b_1$

Critical tumor size at which the angiogenic switch occurs

$1\times {10}^6$

cells

[50]

$S_1$

Concentration of TGF-β necessary to reduce the CD8+ T cell killing rate of tumor cells by half

$7\times {10}^4$

IU L⁻¹

[51]

$u_1$

Decay rate of TGF-β

10

day⁻¹

[50]

$b_K$

Proliferation rate of angiogenic endothelial cells

0.198

day⁻¹

[52]

$K_{max}$

Maximum carrying capacity for blood vessel growth stimulated by TGF-β secreted by tumor cells

$5\times {10}^9$

cells

Est.

$g_1$

TGF-β concentration that gives a half-maximal proliferation rate of endothelial cells

$1\times {10}^4$

IU L⁻¹

Est.

$d_K$

Growth inhibition coefficient of endothelial cells by tumor cells

$5\times {10}^{-8}$

cell^−2/3 day⁻¹

Est. from [53]

${\lambda }_T$

Suppressive effect of Treg cells on wild-type and mutant tumor cell kill rate by NK cells

$1.59\times {10}^{-9}$

L cell⁻¹

[45]

w

Rate of Treg cell production from circulating lymphocytes

$4.698\times {10}^{-4}$

day⁻¹

[45]

$u_R$

Rate of Treg cell turnover

$3.851\times {10}^{-2}$

day⁻¹

[54]

$p_R$

Rate of IL-2-induced Treg cell proliferation

$3.598\times {10}^{-2}$

day⁻¹

[49]

$g_R$

Concentration of IL-2 necessary for half-maximal activation of Treg cells

11.027

IU L⁻¹

[49]